78 related articles for article (PubMed ID: 23758591)
1. Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands.
Fiandra L; Mazzucchelli S; De Palma C; Colombo M; Allevi R; Sommaruga S; Clementi E; Bellini M; Prosperi D; Corsi F
ACS Nano; 2013 Jul; 7(7):6092-102. PubMed ID: 23758591
[TBL] [Abstract][Full Text] [Related]
2. Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules.
Johnston AP; Kamphuis MM; Such GK; Scott AM; Nice EC; Heath JK; Caruso F
ACS Nano; 2012 Aug; 6(8):6667-74. PubMed ID: 22872125
[TBL] [Abstract][Full Text] [Related]
3. [Targeted detecting HER2 expression with recombinant anti HER2 ScFv-GFP fusion antibody].
Gao G; Chen C; Yang Y; Yang H; Wang J; Zheng Y; Huang Q; Hu X
Sheng Wu Gong Cheng Xue Bao; 2012 Aug; 28(8):1002-14. PubMed ID: 23185900
[TBL] [Abstract][Full Text] [Related]
4. HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice.
Corsi F; Fiandra L; De Palma C; Colombo M; Mazzucchelli S; Verderio P; Allevi R; Tosoni A; Nebuloni M; Clementi E; Prosperi D
ACS Nano; 2011 Aug; 5(8):6383-93. PubMed ID: 21790185
[TBL] [Abstract][Full Text] [Related]
5. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
7. High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles.
Baiu DC; Artz NS; McElreath MR; Menapace BD; Hernando D; Reeder SB; Grüttner C; Otto M
Nanomedicine (Lond); 2015 Oct; 10(19):2973-2988. PubMed ID: 26420448
[TBL] [Abstract][Full Text] [Related]
8. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
10. Gum Arabic coated magnetic nanoparticles with affinity ligands specific for antibodies.
Batalha IL; Hussain A; Roque AC
J Mol Recognit; 2010; 23(5):462-71. PubMed ID: 20119950
[TBL] [Abstract][Full Text] [Related]
11. Biocompatible functionalization of polymersome surfaces: a new approach to surface immobilization and cell targeting using polymersomes.
Egli S; Nussbaumer MG; Balasubramanian V; Chami M; Bruns N; Palivan C; Meier W
J Am Chem Soc; 2011 Mar; 133(12):4476-83. PubMed ID: 21370858
[TBL] [Abstract][Full Text] [Related]
12. Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells.
Sommaruga S; Lombardi A; Salvadè A; Mazzucchelli S; Corsi F; Galeffi P; Tortora P; Prosperi D
Appl Microbiol Biotechnol; 2011 Aug; 91(3):613-21. PubMed ID: 21538107
[TBL] [Abstract][Full Text] [Related]
13. Targeting of cancer cells using click-functionalized polymer capsules.
Kamphuis MM; Johnston AP; Such GK; Dam HH; Evans RA; Scott AM; Nice EC; Heath JK; Caruso F
J Am Chem Soc; 2010 Nov; 132(45):15881-3. PubMed ID: 20977221
[TBL] [Abstract][Full Text] [Related]
14. Dependence of nanoparticle-cell recognition efficiency on the surface orientation of scFv targeting ligands.
Mazzucchelli S; Sommaruga S; O'Donnell M; Galeffi P; Tortora P; Prosperi D; Colombo M
Biomater Sci; 2013 Jul; 1(7):728-735. PubMed ID: 32481827
[TBL] [Abstract][Full Text] [Related]
15. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody.
Kocbek P; Obermajer N; Cegnar M; Kos J; Kristl J
J Control Release; 2007 Jul; 120(1-2):18-26. PubMed ID: 17509712
[TBL] [Abstract][Full Text] [Related]
16. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
Steinhauser I; Spänkuch B; Strebhardt K; Langer K
Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
[TBL] [Abstract][Full Text] [Related]
18. Surface-enhanced Raman scattering detection and tracking of nanoprobes: enhanced uptake and nuclear targeting in single cells.
Gregas MK; Scaffidi JP; Lauly B; Vo-Dinh T
Appl Spectrosc; 2010 Aug; 64(8):858-66. PubMed ID: 20719048
[TBL] [Abstract][Full Text] [Related]
19. Single-domain protein A-engineered magnetic nanoparticles: toward a universal strategy to site-specific labeling of antibodies for targeted detection of tumor cells.
Mazzucchelli S; Colombo M; De Palma C; Salvadè A; Verderio P; Coghi MD; Clementi E; Tortora P; Corsi F; Prosperi D
ACS Nano; 2010 Oct; 4(10):5693-702. PubMed ID: 20825223
[TBL] [Abstract][Full Text] [Related]
20. Multiple presentation of Scfv800E6 on silica nanospheres enhances targeting efficiency toward HER-2 receptor in breast cancer cells.
Mazzucchelli S; Verderio P; Sommaruga S; Colombo M; Salvadè A; Corsi F; Galeffi P; Tortora P; Prosperi D
Bioconjug Chem; 2011 Nov; 22(11):2296-303. PubMed ID: 22010849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
